摘要
目的:探讨孟鲁司特口服治疗儿童咳嗽变异性哮喘(CVA)的临床疗效。方法:将48例4-14岁确诊为CVA的患儿依数字随机法分为治疗组与对照组。治疗组25例,口服孟鲁司特每日1次(6-14岁5 mg,4-5岁4 mg),并吸入布地奈德气雾剂1次(每次1喷,含量200μg),对照组23例吸入布地奈德每日两次(每次1喷,每喷含量200μg),两组均使用储雾罐吸入,疗程12周。观察3 d、1周、2周、4周和12周咳嗽改善情况,测量治疗前及治疗后1周、2周、4周、12周呼气峰流速(PEF),计算PEF占预计值的百分比(PEF%pred),记录患儿对治疗的感受及治疗中的不良反应。结果:治疗后两组咳嗽均有改善,治疗组治疗后3 d、1周咳嗽改善情况明显优于对照组(P〈0.01),第2周时两组无显著性差异(P〉0.05),两组治疗后PEF%pred与治疗前相比,均有明显上升(P〈0.01),治疗组治疗后1周、2周、4周PEF%pred改善程度优于对照组(P〈0.01)。结论:孟鲁司特治疗儿童CVA起效快、疗效佳,可减少糖皮质激素用量。
Objective: To investigate the clinical curative effect of Montelukast taken orally on cough variation asthma(CVA) in children. Methods: All the 48 examples aged from 4 - 14 years old diagnosed CVA were divided into treatment group (n = 25 ) and control group (n = 23 ) randomly. The children in treatment group took Montelukast orally 1 time a day(5mg/time for 6- 14 years old, 4 mg/time for 4- 6 years old) and inhaled Budesenide Aerosol qd (each time 1 spurt, content 200μg), and those in control group inhaled Budesenide Aerosol bid(each time 1 spurt, content 200μg ) only. Both groups inhaled Budesonide Aerosol with spacers and were observed for 12 weeks. Symptoms, peak expiratory flow rates (PEF), percentage of PEF to predicted value( PEF% pred) and side effects were recorded before and after treatment 3rd day, 1 week, 2 week, 4 week and 12 week. Result: Both of the groups could reduce symptoms such as cough, and treatment group had better effect than control group(P 〈 0.01 ) at 3rd day, 1 week after treatment, but there was not different between the two groups from 2 weeks after treatment. PEF% pred increased in both the groups after treatment, but it increased more remarkable 1 week, 2 week and 4 week after treatment in treatment group than in control group. Conclusion: Montelukast has more quickly and better effect on CVA in children than glucocorticoid and can reduce the dose used of the latter.
出处
《现代临床医学》
2007年第6期434-435,共2页
Journal of Modern Clinical Medicine